Background: Vitamin D 3 possesses anti-inflammatory and modulatory properties in addition to its role in calcium and phosphate homeostasis. Upon activation, macrophages (M) can initiate and sustain pro-inflammatory cytokine production in inflammatory disorders and play a pathogenic role in certain cancers. Purpose: The main purpose of this study was to encapsulate and specifically target calcitriol to macrophages and investigate the anti-inflammatory properties of calcitriol in vitro and in vivo. Methods: In this study we have designed and developed near-infrared calcitriol PEGylated nanoparticles (PEG-LNP(Cal)) using a microfluidic mixing technique and modified lipid nanoparticles (LNPs) to target the M specific endocytic receptor CD163. We have investigated LNP cellular uptake and anti-inflammatory effect in LPS-induced M in vitro by flow cytometry, confocal microscopy and gene expression analyses. LNP pharmacodynamics, bio-distribution and organ specific LNP accumulation was also investigated in mice in vivo. Results: In vitro, we observed the specific uptake of PEG-LNP(Cal)-hCD163 in human M, which was significantly higher than the non-specific uptake of control PEG-LNP(Cal)-IgG(h) in M. Pretreatment with encapsulated calcitriol was able to attenuate intracellular TNF-expression, and M surface marker HLA-DR expression more efficiently than free calcitriol in LPS-induced M in vitro. Encapsulated calcitriol diminished mRNA gene levels of TNF-, NF-B, MCP-1 and IL-6, while upregulating IL-10. TNF-and IL-6 protein secretion also decreased. In mice, an in vivo pharmacodynamic study of PEG-LNP(Cal) showed a rapid clearance of IgG and CD163 modified LNPs compared to PEG-LNP(Cal). Antibody modified PEG-LNP(Cal) accumulated in the liver, spleen and kidney, whereas unmodified PEG-LNP(Cal) accumulation was only observed in the liver. Conclusion: Our results show that calcitriol can be effectively targeted to M. Our data confirms the anti-inflammatory properties of calcitriol and this may be a potential way to deliver high dose bioactive calcitriol to M during inflammation in vivo.
Introduction
Nanoparticle drug-delivery systems are promising tools used for delivering active molecules to target sites of action in vivo, resulting in increased bioavailability and drug efficacy and minimized off-target adverse side effects. Several targeted nanoparticle drug-delivery systems have been reported in advanced trial phases for certain cancers 1 and have the potential for the treatment of autoimmune disorders and inflammatory diseases such as nonalcoholic fatty-liver disease (NAFLD). 2, 3 Macrophages (Mϕ) are important players in the pathogenesis of, for example, obesity-associated type 2 diabetes, inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and rheumatoid arthritis and in certain cancers. [4] [5] [6] [7] These phagocytes are plastic, heterogenic immune cells capable of adapting, polarizing, and altering cytokine production and cell surface marker expression according to their microenvironment. 8 Tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6 are inflammatory cytokines released by Mϕ upon endotoxin challenge 9 and have been linked to insulin resistance, obesity, and chronic low-grade inflammatory disorders. 10, 11 Specific pro-or anti-inflammatory Mϕ subsets, mimicking in vivo phenotypes, can be generated by stimulation with either interferon-γ and lipopolysaccharide (LPS) or IL-13 and IL-4 in vitro. 12 In addition, Mϕ can also be characterized by their function as inhibitory Mϕ mediated by, for example, nitric oxide or as wound healing Mϕ by producing orthinine. 13 CD163 is the hemoglobin-haptoglobin scavenger receptor and is exclusively expressed on circulating monocytes, tissue-resident Mϕ, and tumor-associated Mϕ. Thus, CD163 is an ideal therapeutic target for drug delivery to Mϕ in both inflammatory disorders and cancers. [14] [15] [16] The physiological role of vitamin D 3 and its metabolite in calcium/phosphate homeostasis and bone metabolism has been elucidated. 17 Pre-vitamin D 3 is produced in the skin and transported by vitamin D-binding protein to the liver, where it is modified by Cyp27a1 into 25(OH)D 3 . In the kidneys, Cyp27b1 converts 25(OH)D 3 into bioactive 1,25(OH) 2 D 3 (calcitriol). 18 Besides the classical role of calcitriol, there is evidence showing that calcitriol has both immunoregulatory and anti-inflammatory properties, which influence innate and adaptive immune responses. 7 Most immune cells (eg, monocytes and Mϕ, 19 lymphocytes, dendritic cells, 20 NK cells, and activated T and B cells 21, 22 ) express both the nuclear vitamin D receptor (VDR) and Cyp27b1. 23 VDR, calcitriol, and the retinoic X receptor complex together and bind to the vitamin D responsive element resulting in nonclassical gene regulation of immune cell proliferation, differentiation, and apoptosis.
Vitamin D deficiency may also be associated with chronic low-grade inflammation, insulin resistance, and type 2 diabetes, 24 and the use of calcitriol as an anti-inflammatory and anticancer agent has been reported in a number of studies (eg, in type 2 diabetes, 11 rheumatoid arthritis, 7 colon cancer, 25 and preclinical anticancer trials 26 ). However, the risk of developing hypercalcemia prevents systemic administration. 27 Chen et al demonstrated that vitamin D-VDR signaling suppresses LPS-mediated inflammation by blocking nuclear factor (NF)-κB activation and suppressing miR-155, resulting in increased SOCS1 translation and thereby enhancing negative feedback regulation of LPS-mediated inflammatory response in murine RAW 264.7 cells. 28 It has been reported that VDR together with calcitriol is able to attenuate NF-κB transcriptional activity through the reduced degradation of IκBα in co-transfected HEK-293 cells. 29 Calcitriol is able to counteract the effects of FGF-23 to induce TNF-α in RAW 264.7 cells. 30 Delivering encapsulated calcitriol to, for example, EGFR tyrosine kinase inhibitor-resistant lung cancer or to Mϕ involved in NASH has demonstrated effective cellular uptake and drug efficacy. 2, 31 In the present study, we developed calcitriol lipid nanoparticles (LNP(Cal)) and PEGylated calcitriol lipid nanoparticles (PEG-LNP(Cal)) with a core of triolein-POPC (2-oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine), as reported by Zhigaltsev et al. 32 PEG-LNPs have an improved half-life and circulation time in vivo compared to conventional LNPs 1 and are able to avoid rapid uptake by nontarget cells. Several studies have shown that the improved half-life of PEG-LNPs results in the increased accumulation of LNPs in tumor and inflamed areas, where increased presence of immune cells is observed in certain cancers and inflammatory diseases. 33, 34 In this study, we targeted PEG-LNP(Cal) to the Mϕ endocytic scavenger receptor CD163 using an anti-CD163 monoclonal antibody (mAB) in order to investigate the specific uptake and effect of calcitriol on Mϕ. Specifically targeting LNPs to improve drug molecule uptake by selected cells, thereby improving drug efficacy and the therapeutic index, is a promising approach for the treatment of both cancers and immune-mediated inflammatory diseases.
Materials and methods Materials
Rat anti-mouse CD163 antibody (clone: E10B10), humanized antihuman CD163 antibody (clone: KN2/ NRY), denoted as αmCD163 and αhCD163, 35 polyclonal rabbit-antihuman CD163 antibody, and CD163-transfected Chinese hamster ovarian (CHO) cells 36 were produced as previously described. 35 Human IgG (cat no 62-8400) and DID′ oil:DiIC 18 (5) oil (1,1′-dioctadecyl-3,3,3′,3′tetramethylindodicarbocyanine perchlorate) (D307) were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Glyceryl trioleate (triolein) (cat no T7140-1G), POPC (42773; 100 mg), rat IgG (I4131; 10 mg), brefeldin A (B6542; 5 mg), and saponin (47036-50G-F) were obtained from Sigma-Aldrich Co (St Louis, MO, USA). pNP-PEG3400-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was obtained from Anders Etzerodt (Institute International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 52.11.211 .149 on For personal use only. animals Nine-week-old RjOrl:SWISS and C57BL/6JRj mice were supplied by Janvier-Labs (Le Genest-Saint-Isle, France) and housed at least for 1 week for acclimatization prior to the experiments at the Biomedical Animal Facility (Aarhus University, Bartholin Building). The mice were housed according to Danish legislation rules and EU Directive 2010/63 on the protection of animals used for scientific purposes in groups of three to four in individually ventilated cages (Tecniplast, Buguggiate, Italy). The mice were subjected to a 12-hour light/12-hour dark schedule and were fed standard chow (Altromin #1324, Lage, Germany) and provided tap water ad libitum throughout the experiment. The animals were given nesting material, shredded paper strips, and wooden squares as environmental enrichment. Bedding consisted of aspen wood chips from Tapvei, Finland.
At the end of the study, the mice were sacrificed by cervical dislocation. All animal studies were performed with the permission of the Danish Animal Experiments Inspectorate (J no 2014-15-0201-00377). All the animal experiments performed complied with the EU Directive (2010/63) as well as national and international legislations, including the Animal Welfare Policy at Aarhus University.
Preparation of calcitriol lNPs
LNPs were formulated using a microfluidic mixing method on a NanoAssemblr ® (Precision NanoSystems, Vancouver, BC, Canada). 32 Conventional LNPs ± calcitriol (LNP(c) or LNP(Cal) were prepared from a mixture of triolein, POPC, and ± calcitriol. Chloroform was evaporated from pNP-PEG3400-DOPE to prepare PEGylated ± calcitriol LNPs (PEG-LNP(c) or PEG-LNP(Cal)) for post-modification. The ethanol-lipid mixture consisted of POPC, triolein, calcitriol, DID, DSPE-PEG2000, and pNP-PEG3400-DOPE. The lipid composition molar ratios for all types of LNP formulations are listed in Table 1 . All lipids were dissolved and vortexed in absolute EtOH. The EtOH-lipid solution was injected into the first inlet, and citrate-buffered saline (CBS) buffer (pH 5.0; 5 mM citric acid, 150 mM NaCl) was injected into the second inlet. LNP formulations were rapidly mixed, with a flow rate ratio of 1:5 and a total flow rate of 12 mL/min. LNP formulations for antibody conjugation were dialyzed twice against CBS buffer (pH 5) overnight at 4°C. Conventional LNPs were prepared in PBS and dialyzed twice against PBS (pH 7.2) overnight at 4°C. All LNP formulations were tested by dynamic light scattering (DLS) (Wyatt Technology Europe GmbH, Dernbach, Germany) to determine their size (radius, nM) and polydispersity. To determine encapsulation efficiency, 50 μL LNP samples were analyzed by reverse phase hydrophobic chromatography using a Dionex Ultimate 3000 HPLC System (GE Healthcare Europe GmbH, Freiburg, Germany) applying an Ascentis ® C18 column (10 cm × 3 mM, 3 μm) (Sigma-Aldrich Co), and UV absorbance at 240 nM with the following gradient: 90%, 0.1% TFA in H 2 
2832
Rafique et al pNP-PEG3000-DOPE, synthesized as described by Torchilin et al, 37 was incorporated into the surface of the LNPs (0.5% of the total lipid). The antibody insertion reaction was pH dependent and performed by mixing the LNP formulation (pH 5.0), protein 1.3 mg/mL (molar ratio 1,000:1), and adding borate-buffered saline (pH 8.5; boric acid 100 mM, NaCl 150 mM, sodium tetraborate 25 mM). The reaction was incubated overnight at 4°C following dialysis twice against PBS (pH 7.2) at 4°C. 37, 38 Total protein concentration was measured using a Pierce BCA protein micro assay (Thermo Fisher Scientific). SPR analyses were conducted to test PEG-LNP(Cal)-αCD163 binding to human or murine CD163 using a Biacore 3000 instrument (Biacore, Uppsala, Sweden). 39 Biacore sensor chips were activated with N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide and 0.05 M N-hydroxysuccinimide. Recombinant human and murine CD163 were immobilized in 10 mM sodium acetate (pH 4.0), and the remaining binding positions were blocked by 1 M ethanolamine (pH 8.5). The attachment procedure resulted in immobilized 0.0483 pmol human CD163/mm 2 and murine CD163/mm 2 in the range of 0.01-0.05 pmol murine CD163/mm 2 . LNP samples were tested in three different concentrations (total antibody), 5, 2.5, and 1.25 μg/mL, including a control antibody with CaHBS running buffer (10 mM Hepes, 150 mM NaCl, 3 mM Ca 2 Cl 2 + 0.05% Tween 20, pH 7.4). The flow cells were regenerated with 500 mM phosphoric acid (pH 1.3), and data were analyzed using the Biomolecular Interaction Analysis evaluation program. 
Purification of human mononuclear cells from buffy coats
Buffy coats from healthy donors were diluted with 0.9% NaCl, layered on to a Histopaque ® -1077 (Sigma-Aldrich Co), and centrifuged at 400×g at room temperature (RT) for 30 minutes without brake. The opaque interface containing mononuclear cells was added to wash buffer containing EDTA (D-PBS/2% FBS/1 mM EDTA), gently aspirated, and centrifuged at 200×g for 10 minutes at RT without brake. The monocytes were purified using an EasySep ® Human CD14 Positive Enrichment kit (cat no 18058) and a Silver EasySep ® Magnet (cat no 18001). Mononuclear cell suspensions were prepared at a concentration of 5×10 7 cells/mL in D-PBS/2% FBS/1 mM EDTA. Purification of the monocytes was performed following the EasySep ® protocol. The monocytes were resuspended in RPMI 1640/penstrep/10% FBS/100 ng/mL macrophage colony-stimulating factor/10 ng/mL granulocyte-macrophage colony-stimulating factor for Mϕ differentiation. The cell cultures were incubated at 37°C under a humidified atmosphere of 95% air and 5% CO 2 . All monocyte/Mϕ cell cultures were supplemented with fresh medium every second day, and fully differentiated Mϕ were ready for in vitro studies after a 6-day incubation period.
In vitro Mϕ setups
Fully differentiated Mϕ (1×10 6 Mϕs/mL) were seeded in sixwell plates for 24 hours. Prior to stimulation, the cell culture medium was replaced with RPMI/PS/10% CS-FBS, and Mϕ were incubated with calcitriol, LNP(Cal), PEG-LNP(Cal), PEG-LNP(Cal)-IgG, and PEG-LNP(Cal)-αhCD163 for 24 hours at 37°C in 5% CO 2 /95% air, following LPS challenge (1 μg/mL LPS for 4 hours). A total of 10 μM dexamethasone for 24 hours was used as the positive control. Mϕ were harvested with pre-warmed lidocaine buffer (PBS/0.5% BSA/5 mM EDTA/4 mg/mL lidocaine) for flow cytometry and in RNeasy lysis buffer buffer with β-mercaptoethanol (Qiagen NV) for RNA purification.
Flow cytometry
To evaluate cellular uptake and the effect of encapsulated calcitriol, Mϕ were incubated with DID-fluorescent PEG-LNP(Cal), PEG-LNP(Cal)-IgG, and PEG-LNP(Cal)-αhCD163 ranging from 0.5 to 100 nM for 24 hours (RPMI 1640/penstrep/10% CS-FBS at 37°C, 5% CO 2 /95% air). The culture medium was collected and Mϕ were detached using lidocaine buffer (PBS/0.5% BSA/5 mM EDTA/4 mg/mL lidocaine from Sigma-Aldrich Co) following washing steps with PBS/0.5% BSA/0.09% NaN 3 (pH 7.4). To evaluate the 
rNa extraction and gene expression analysis by qPcr
To investigate the effect of encapsulated calcitriol on pro-and anti-inflammatory cytokine mRNA gene expression, RNA was extracted using QIAamp RNA Blood Mini kits (Qiagen NV) according to the manufacturer's protocol. First, 100 ng of total RNA was transcribed into cDNA using the following mix: MgCl 2 solution 25 mM, 10× PCR buffer, Oligo 50 μM, RNAse inhibitor, RT enzyme, and Ultrapure dNTP mix (Thermo Fisher Scientific). RT-qPCR reactions were run in duplicates containing SYBR Green I Master Mix (Hoffman-La Roche), ddH 2 O, and target forward/reverse primers, under the following conditions: preincubation at 95°C for 10 minutes followed by cycled amplification at 95°C for 10 seconds, with primer-dependent annealing temperature for 20 seconds, and 72°C for 5 seconds for 50 cycles. RT-qPCR was carried out using a LightCycler ® 480 instrument. (Hoffman-La Roche). NormFinder ® software was used to determine the stable housekeeping gene. 40 The relative mRNA concentration in each sample was calculated by using the second derivative max method. The target gene expression level of each sample was divided by the associated housekeeping gene GAPDH expression level. The mRNA ratios of the target gene/housekeeping gene were normalized to the untreated control. All primers and annealing temperatures are listed in Table 2 .
elIsa for the detection of TNF-α and Il-6
To evaluate TNF-α and IL-6 protein secretion in cell culture supernatants after treatment with calcitriol LNPs we used the 
In vivo imaging and biodistribution
To investigate the biodistribution and tissue uptake of DID PEG-LNP(Cal) and targeted DID PEG-LNP(Cal) in vivo, SWISS mice (n=1/group) were injected intravenously (IV) with an LNP solution (0.05-0.1 mg/kg 1.25(OH) 2 D 3 ). The animals were anesthetized with 3.75% isoflurane (IsoFlo Vet; Orion Pharma, Espoo, Finland) and scanned in a Xenogen IVIS ® Spectrum in vivo imaging system (PerkinElmer Inc, Waltham, MA, USA) equipped with filters for ex680/em700 visualization. The system was used to measure LNP accumulation at 15, 45, 90, 150, and 210 minutes postinjection.
Pharmacodynamic study
To evaluate the clearance of encapsulated calcitriol in vivo, healthy C57BL/6 mice (n=4/group) were injected in the tail vein with either saline water, DID PEG-LNP(Cal), DID PEG-LNP(Cal)-IgG, or DID PEG-LNP(Cal)-αmCD163 (0.1 mg/ kg calcitriol). The first blood sample (tongue blood) was collected 1 minute after injection. Multiple blood samples were collected from the tail vein at T=30 minutes, T=1, 2, 4, 6, and 24 hours after intravenous injection in 20 μL Na-heparinized pipettes (Vitrex Medical A/S, Herlev, Denmark). All blood 
Results
Vitamin D 3 encapsulation efficiency and binding analysis of anti-cD163 antibody-modified LNPs
The size distribution of LNP(Cal) and PEG-LNP(Cal) was in the range of 30-35 nM radius, as measured using the DLS technique. The LNP(c) and PEG-LNP(c) mean particle radii were in the range of 35-45 nM ( Figure 1A and B ). Particle size distribution of PEG-LNP(Cal) prior to modification is shown in Figure 1C . The LNP mean particle radius was in the range of 50-60 nM post-IgG and anti-CD163 mAB modification (data not shown). Total calcitriol entrapment was determined by reverse phase HPLC and LNP(Cal) and PEG-LNP(Cal) were measured at 0.056 and 0.043 mg/mL, respectively, resulting in an encapsulation efficiency of 58%-76% of the total calcitriol input. SPR analysis was performed to study the binding of human and murine PEG-LNP(Cal)-αCD163 to immobilized CD163 protein. Free αCD163 mAB was used as a positive control to evaluate specific binding affinity. We observed efficient binding of PEG-LNP(Cal)-αhCD163 or PEG-LNP(Cal)-αmCD163 in contrast to no binding of LNPs modified with either irrelevant human IgG or rat IgG ( Figure 1D and E) . Stability studies showed that LNP formulations were stable for at least 50 days when stored at 5°C and 26°C, with no change in size and polydispersity. LNP storage at 40°C showed that around day 50, LNP size and polydispersity increased, probably due to particle aggregation (data not shown).
Cellular uptake and specificity of CD163targeted LNPs vs unmodified LNPs
To assess the CD163-mediated cellular uptake of targeted PEG-LNP(Cal) and PEG-LNP(c), human Mϕ were treated with non-targeted IgG and CD163-targeted DID PEG-LNP(Cal) for 24 hours. LNP uptake was investigated by flow cytometry, and histograms revealed a heterogenic expression of CD163 in control Mϕ (Figures 2A and S1A ). We observed an increased uptake of DID-PEG-LNP(Cal)- This indicates that the uptake was CD163 specific and confirms that PEG-LNP(Cal)-αCD163 is internalized through CD163. Similarly, we observed specific uptake of PEG-LNP(Cal)-αCD163 in CHO-CD163 murine cells and no uptake of PEG-LNP(Cal)-IgG in CHO-CD163 murine cells ( Figure S1C ). Furthermore, CHO-MOCK cells (m) did not take up PEG-LNP(Cal)-IgG and PEG-LNP(Cal)-αCD163. Similar observations apply to the uptake of IgG-and CD163-targeted PEG-LNP(c) in CHO-CD163 and CHO-MOCK murine cells ( Figure S2C ).
effects of encapsulated calcitriol on proinflammatory cytokines and chemokines in Mϕ
To examine the anti-inflammatory effects of calcitriol, Mϕ were incubated with non-targeted PEG-LNP(Cal) and Figure 3E ), although this was not as effective as the positive glucocorticoid control, dexamethasone ( Figure S2A-F) .
In addition, CD163 mRNA gene expression was not affected by pretreatment with either PEG-LNP(Cal) or targeted PEG-LNP(Cal) ( Figure 3F ). Since TNF-α and IL-6 are considered as highly important markers in inflammation because they are involved and overexpressed in most inflammatory states, we decided to assess TNF-α and IL-6 protein secretion in LPS-stimulated Mϕ pretreated with PEG-LNP(Cal) and targeted PEG-LNP(Cal) by ELISA. 41 Both PEG-LNP(Cal) and targeted PEG-LNP(Cal) significantly suppressed TNF-α secretion in a dose-dependent manner as compared to treatment with free calcitriol in LPS-stimulated Mϕ (data not shown). Similarly, IL-6 secretion was slightly reduced, albeit not significantly, after treatment with both PEG-LNP(Cal) and targeted PEG-LNP(Cal) ( Figure 3G 
In vivo biodistribution and pharmacokinetic study of cD163targeted calcitriol lNPs vs non-targeted calcitriol lNPs in mice
In order to address specific delivery and evaluate the biodistribution of the LNP system in healthy SWISS mice in vivo, DID PEG-LNP(Cal) were modified with αmCD163 or the corresponding control rat IgG. Live animals were imaged at 15, 45, 90, 150, and 210 minutes post-IV administration using a Xenogen IVIS ® in vivo imaging system. Both PEG-LNP(Cal)-IgG and PEG-LNP(Cal)-αmCD163 showed increased accumulation in the upper abdominal part of the animals as compared to PEG-LNP(Cal), which seemed to circulate in the blood for a longer period of time ( Figure 4A ). An in vivo pharmacodynamic study was performed to assess the clearance of PEG-LNP(Cal) and IgG-and anti-CD163 mAB-modified PEG-LNP(Cal). Nineweek-old C57BL/6JRj mice (n=4) were injected IV with LNP formulations (0.1 mg/kg), and 20 μL blood samples were collected at seven different time points (T=1 and 30 minutes, and 1, 2, 4, 6, and 24 hours). The LNP DID fluorescence intensity was measured using a Xenogen in vivo imaging system ( Figure 4B ). Due to dilution of the total encapsulated calcitriol concentration in LNP formulations, which likely influenced the total DID fluorescence and particle concentration, a normalization factor was added to all total radiant efficiencies. We observed rapid clearance of PEG-LNP(Cal)-IgG and PEG-LNP(Cal)-αmCD163 in the first 30 minutes and up to 2 hours postinjection, compared to the prolonged circulation of PEG-LNP(Cal). We also observed a significant difference in the clearance of targeted 
Discussion
To the best of our knowledge, this is the first study describing the targeting of calcitriol specifically to Mϕ using antibody-modified LNPs. Monocytes and Mϕ are key players in several inflammatory disorders and cancers, and specific targeting of these cells has been shown to result in increased drug efficacy with fewer side effects. 35, 43, 44 In the case of vitamin D 3 the risk of hypercalcemia hinders the use of high dose systemic treatment. Recent attempts have been made to overcome this involving the encapsulation of calcitriol in nanoemulsions, liposomes, and PLGA nanoparticles. 2, 3, 31, 45 Although such nanoparticles accumulate at the sites of inflammation or in tumor tissue due to the enhanced permeability and retention effect, 46, 47 further improvement of the therapeutic index may be obtained by specific targeting of the inflammatory cells, in essence reducing the adverse effects of toxic therapeutic agents caused by systemic uptake. We used the Mϕ specific receptor CD163 as a target for antibodymodified LNPs. CD163 is an obvious target due to its high expression on Mϕs in general and especially at sites of inflammation and cancer, 48, 49 as well as its endocytic nature, which results in the daily removal of gram levels of hemoglobin from the circulation. 44, 50 We successfully produced stable PEGylated calcitriol LNPs and were able to conjugate human and mouse mABs with a strong affinity for CD163 to the particles, as demonstrated by SPR analysis. Single cell analysis showed an increased uptake of PEG-LNP(Cal)-αCD163 by Mϕ compared to the internalization of PEG-LNP(Cal) and International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 52.11.211 .149 on For personal use only.
PEG-LNP(Cal)-IgG. Confocal microscopy confirmed that CD163-targeted calcitriol particles were effectively taken up by CD163-expressing CHO cells, whereas control IgGmodified particles were not. In Mϕ, we observed increased uptake of anti-CD163-modified calcitriol LNPs and a modest uptake of IgG-modified calcitriol LNPs. The latter result is probably due to the nonspecific uptake of IgG particles by Fc receptors. In an in vitro system of LPS stimulation of Mϕ, anti-CD163-modified, IgG-modified, and non-targeted calcitriol LNPs all showed a strong inhibitory effect on the mRNA gene expression of pro-inflammatory markers (TNF-α, NF-κB, MCP-1, and to a lesser extent, IL-6), but a stimulatory effect on anti-inflammatory IL-10. However, it has been reported that calcitriol induces MCP-1 expression in dendritic cells in multiple sclerosis patients 51 but suppresses LPS-induced MCP-1 in the human monocytic cell line THP-1. 52 The in vitro system, not reflecting the in vivo circulation, precludes the possibility for demonstrating a superior effect of receptor-targeted particles vs unmodified particles, as both types of LNPs will be taken up by Mϕ. Furthermore, even though we observed specific and significant increased internalization of CD163-targeted calcitriol LNPs by Mϕ, this was not fully reflected in the specific inhibitory effect of calcitriol on pro-inflammatory cytokine gene expression, as we observed an inhibitory effect on both IgG-and CD163-targeted and non-targeted LNPs. This may be due to the (short) 24-hour incubation period in vitro, as intracellular drug release and subsequent effects may be more efficient and effective after a longer incubation period (eg, 48-72 hours) with non-targeted and mAB-modified (IgG and CD163) calcitriol LNPs in vitro. Investigating the rate of drug (calcitriol) release in this specific drug-delivery system may also improve our understanding with regard to the lack of increased anti-inflammatory effects of CD163targeted LNPs. Interestingly, we observed a dose-dependent decrease in the surface marker expression of HLA-DR and the co-stimulatory surface molecule CD80 exclusively in DID + LPS-induced Mϕ pretreated with PEG-LNP(Cal)-αCD163. However, we observed a lower CD80 expression in untreated LPS-induced Mϕ. This may be due to the fact that the LPS-induced Mϕ mean fluorescence intensity (MFI) reflects the expression of CD80 in the total Mϕ population, whereas the surface expression of CD80 on PEG-LNP(Cal)-αCD163-treated Mϕ reflects the MFI of DID + Mϕ. This problem could be avoided by treating Mϕ with empty targeted particles. In general, these data support the well-described anti-inflammatory and immunoregulatory role of calcitriol in myeloid cells. 11, [53] [54] [55] [56] [57] We then investigated the biodistribution and tissue accumulation of DID fluorescent non-targeted and mAB-modified (IgG and CD163) LNPs in vivo in mice. The increased circulation of PEG-LNPs in the blood flow could be due to their improved stability as well as the half-life extension of these LNPs, compared to conventional LNPs, which undergo rapid clearance due to destabilization and opsonization of plasma components. 58, 59 However, targeting LNPs toward specific monocyte/Mϕ receptors can provide effective uptake and thereby reduce uptake by other Mϕ subsets. 35 We observed an increased accumulation of both PEG-LNP(Cal)-IgG and PEG-LNP(Cal)-αCD163 in the upper abdomen as compared to PEG-LNP(Cal). Due to the route of injection, mAB-modified calcitriol LNPs are most likely captured by hepatic Mϕ (Kupffer cells) in the liver and by splenic red-pulp Mϕ, as these cells are in direct contact with the bloodstream. Nevertheless, the uptake of IgG-targeted calcitriol LNPs, most likely by the Fc receptor, should also not be underestimated because these particles are also taken up by the majority of Mϕ in the liver and spleen. Interestingly, particle characteristics and the route of administration play a significant role in particle uptake and tissue-specific accumulation. IgG-modified LNP delivery systems administered subcutaneously have been shown to be useful for the targeting of, for example, regional lymph nodes, 60 and orally administered Fc receptor-targeted nanoparticles have been shown to enter systemic circulation through transepithelial transport. 61 In conclusion, our study shows for the first time the targeting of calcitriol specifically to Mϕ. In summary, we demonstrate the uptake and effect of PEGylated and AB-modified calcitriol LNPs on human Mϕ in vitro and bioavailability in vivo. We were able to deliver the bioactive metabolite to Mϕ. The targeting of CD163 for the specific delivery of calcitriol may be a useful approach for the treatment of chronic inflammatory diseases while potentially avoiding adverse side effects.
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